Webster Bank N. A. Has $687,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Webster Bank N. A. boosted its position in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 1.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,351 shares of the company’s stock after purchasing an additional 101 shares during the quarter. Webster Bank N. A.’s holdings in Novo Nordisk A/S were worth $687,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in NVO. Pacific Center for Financial Services lifted its holdings in Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. First PREMIER Bank bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $25,000. CNB Bank acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $26,000. Tyler Stone Wealth Management boosted its position in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $142.74 on Friday. The company has a fifty day moving average price of $135.00 and a 200 day moving average price of $123.54. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $148.15. The firm has a market cap of $640.55 billion, a PE ratio of 49.22, a PEG ratio of 1.42 and a beta of 0.41. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. The company had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Research analysts predict that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NVO has been the topic of a number of recent analyst reports. Argus raised their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. BMO Capital Markets reissued an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Finally, The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Check Out Our Latest Report on Novo Nordisk A/S

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Read More

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.